Neuropathix, Inc. articles

Temple research finds that tweaking CBD may help it curb pain and opioid use in mice

Doylestown-based Neuropathix is running safety tests required to start clinical trials in humans. The compound may help with neuropathy, a severe type of chronic pain associated with cancer treatment.

The next generation of cannabis-inspired medicine might be grown in test tubes instead of greenhouses.

Researchers at Temple University have partnered with Doylestown-based pharmaceutical company Neuropathix to develop a synthetic molecule based on cannabidiol (CBD) that can prov

Jul. 1, 2021

CBD: Perils, Promise and Development for Neuropathic Pain

Cannabidiol, or CBD, is one of several compounds extracted from the cannabis (marijuana) plant. In recent years, CBD has become enormously popular, and its market is believed to be hundreds of millions of dollars. Believers and users of CBD extoll its benefits for inflammation, muscle soreness, pain, anxiety and a whole host of other things, including cancer.

It is, however, very understudied. There is

Dec. 2, 2019

Philly Pharmacologists are Developing a Promising Pain-Relieving CBD Analog Drug

Scientists from Temple’s Lewis Katz School of Medicine and local biopharma company Neuropathix are testing their compound, KLS-13019, which is intended to target chemotherapy-induced pain in cancer patients.

Sara Jane Ward, assistant professor of pharmacology at Temple University’s Lewis Katz School of Medicine, and Douglas Brenneman, chief pharmacologist at Neuropathix, discuss their CBD analog drug. Photograph of Ward by Daniel Burke Photo & Video, LLC; Bren

May. 3, 2021

Neuropathix, Inc. articles

Temple research finds that tweaking CBD may help it curb pain and opioid use in mice

CBD: Perils, Promise and Development for Neuropathic Pain

Philly Pharmacologists are Developing a Promising Pain-Relieving CBD Analog Drug

Contact supplier